Literature DB >> 2862228

Regulation of the concentration of adenosine 3',5'-cyclic monophosphate and the activity of tyrosine hydroxylase in the rat superior cervical ganglion by three neuropeptides of the secretin family.

N Y Ip, C Baldwin, R E Zigmond.   

Abstract

Preganglionic nerve stimulation leads to an acute elevation of tyrosine hydroxylase (TH) activity in the rat superior cervical ganglion. This effect is mediated in part by acetylcholine, acting via nicotinic receptors, and in part by a noncholinergic neurotransmitter. As a first step in an attempt to identify this noncholinergic transmitter, we have examined a number of biogenic amines, purine nucleotides, neuropeptides, and other compounds for their ability to increase TH activity. Secretin, vasoactive intestinal peptide (VIP), and PHI (a 27-amino acid peptide with an NH2-terminal histidine and a COOH-terminal isoleucine amide), all members of the secretin family of peptides, increased TH activity acutely. Human pancreatic growth hormone-releasing factor, glucagon, and gastric inhibitory peptide (three other members of this peptide family) and all other transmitter candidates tested had no effect on this enzyme activity. We have examined the possibility that this peptidergic regulation of TH activity is mediated via changes in adenosine 3',5'-cyclic monophosphate (cAMP) levels. When the six members of the secretin family were tested for their ability to increase cAMP levels in the ganglion, secretin, VIP, and PHI significantly increased this cyclic nucleotide, whereas growth hormone-releasing factor, glucagon, and gastric inhibitory peptide produced no significant effects. The rank orders of potency and of efficacy of secretin, VIP, and PHI in altering TH activity and cAMP levels were identical. Furthermore, a strong correlation was found between the cAMP level and the TH activity in individual ganglia exposed to these peptides. Finally, 8-bromoadenosine 3',5'-cyclic monophosphate and forskolin also increased TH activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862228      PMCID: PMC6565122     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

1.  Further analysis of presence of peptides in dopamine neurons. Cholecystokinin, peptide histidine-isoleucine/vasoactive intestinal polypeptide and substance P in rat supramammillary region and mesencephalon.

Authors:  K Seroogy; Y Tsuruo; T Hökfelt; J Walsh; J Fahrenkrug; P C Emson; M Goldstein
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

2.  Vasoactive intestinal polypeptide concentrations in heart atria of hypothyroid rats.

Authors:  J Kuncová; J Slavíková
Journal:  Exp Clin Cardiol       Date:  2001

3.  Patch cramming reveals the mechanism of long-term suppression of cyclic nucleotides in intact neurons.

Authors:  Bhavya Trivedi; Richard H Kramer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

4.  Mechanisms mediating pituitary adenylate cyclase-activating polypeptide depolarization of rat sympathetic neurons.

Authors:  M M Beaudet; R L Parsons; K M Braas; V May
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

5.  Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.

Authors:  Misu Lee; Beatrice Waser; Jean-Claude Reubi; Natalia S Pellegata
Journal:  Mol Endocrinol       Date:  2012-06-12

6.  Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury.

Authors:  R P Mohney; R E Zigmond
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

7.  Peptidergic modulation of the membrane potential of the Schwann cell of the squid giant nerve fibre.

Authors:  P D Evans; V Reale; J Villegas
Journal:  J Physiol       Date:  1986-10       Impact factor: 5.182

8.  Phenotypic plasticity in adult sympathetic neurons: changes in neuropeptide expression in organ culture.

Authors:  R E Zigmond; H Hyatt-Sachs; C Baldwin; X M Qu; Y Sun; T W McKeon; R C Schreiber; U Vaidyanathan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

Review 9.  Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity?

Authors:  Sanna Laurila; Eleni Rebelos; Miikka-Juhani Honka; Pirjo Nuutila
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-04       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.